Literature DB >> 15895885

Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis.

Z Nagy1, L Czirják.   

Abstract

OBJECTIVE: Investigation of the impact on survival of inflammatory parameters (C-reactive protein, ESR), markers of immune activation (serum soluble IL-2 receptor, soluble CD30), and N-terminal propeptide of type III procollagen levels (PIIINP) in systemic sclerosis (SSc).
METHODS: In a prospective follow up study, clinical and laboratory data of 80 patients with SSc were evaluated. Kaplan-Meier survival curves and Cox proportional hazards model were used. Eighty cases with SSc were evaluated. Female/male ratio was 8/72. The mean (+/-SD) age was 49.3 (+/-12.3) years, 16 patients died during our mean follow up of 58.1 months.
RESULTS: In the univariate analysis, the presence of a C-reactive protein level above 20 mg/l was an unfavourable prognostic sign (p<0.001). Increased level of PIIINP level also caused an unfavourable outcome of disease (p<0.001). Conversely, increased ESR, soluble IL-2 receptor, soluble CD30 levels, presence of anaemia, did not influence the prognosis. Male gender (p<0.005), diffuse cutaneous SSc, clinically significant lung involvement (p<0.001), kidney (p<0.0001), cardiac (p<0.05) manifestations including pericarditis (p<0.02) were unfavourable prognostic signs by univariate Kaplan-Meier method. Multivariate analysis by Cox proportional hazards model showed that the increased level of PIIINP (RR: 6.98), and presence of diffuse cutaneous SSc (RR: 5.14) were independent unfavourable prognostic signs.
CONCLUSIONS: An increased collagen metabolism unfavourably influences the outcome of SSc. This parameter may also be a potential candidate as a disease activity marker.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15895885

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  13 in total

1.  Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis.

Authors:  Xiang Guo; Brandon W Higgs; Anne C Bay-Jensen; Morten A Karsdal; Yihong Yao; Lorin K Roskos; Wendy I White
Journal:  J Invest Dermatol       Date:  2015-05-20       Impact factor: 8.551

Review 2.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 3.  Application of biomarkers to clinical trials in systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

4.  Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?

Authors:  Joanna Busquets; Francesco Del Galdo; Eugene Y Kissin; Sergio A Jimenez
Journal:  Rheumatology (Oxford)       Date:  2010-03-04       Impact factor: 7.580

5.  Circulating biomarkers of systemic sclerosis - interstitial lung disease.

Authors:  Anna-Maria Hoffmann-Vold; Håvard Fretheim; Chantal Meier; Britta Maurer
Journal:  J Scleroderma Relat Disord       Date:  2020-01-06

6.  Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist.

Authors:  Balsam El Ghoul; Tarek Squalli; Aude Servais; Caroline Elie; Vannary Meas-Yedid; Christine Trivint; Jill Vanmassenhove; Jean-Pierre Grünfeld; Jean-Christophe Olivo-Marin; Eric Thervet; Laure-Hélène Noël; Dominique Prié; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

Review 7.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

8.  Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran.

Authors:  Hadi Poormoghim; Elham Andalib; Arash Jalali; Afshin Ghaderi; Ali Ghorbannia; Nazanin Mojtabavi
Journal:  Rheumatol Int       Date:  2016-04-09       Impact factor: 2.631

9.  Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?

Authors:  Xiaochun Liu; Maureen D Mayes; Claudia Pedroza; Hilda T Draeger; Emilio B Gonzalez; Brock E Harper; John D Reveille; Shervin Assassi
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-08       Impact factor: 4.794

Review 10.  Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.

Authors:  Alsya J Affandi; Timothy R D J Radstake; Wioleta Marut
Journal:  Semin Immunopathol       Date:  2015-07-14       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.